Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02323646 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of Telapristone Acetate (Proellex®) Administered Vaginally for the Treatment of Uterine Fibroids
A Phase 2 study, sponsored by Repros Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 42
- Enrollment target
NCT02323646 is a Phase 2 study that has completed, run by Repros Therapeutics. The registered enrollment target is 42 participants.
The verdict
NCT02323646, a Phase 2 study, has completed, sponsored by Repros Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 42 participants
- Enrollment target
Study Summary
The primary objective of this study is to determine the safety and efficacy of two vaginal doses of Proellex® administered for up to 2 courses of treatment (18 weeks each), each separated by an Off-Drug Interval (ODI), to premenopausal women with symptomatic uterine fibroids.
Interventions
- DRUG Placebo
- DRUG Telapristone Acetate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2015-02-12 |
| Est. Completion | 2017-04-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02323646
The ClinicalTrials.gov registry entry for NCT02323646 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Repros Therapeutics, which has 50 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02323646 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02323646 about?
NCT02323646 is a clinical study titled "Safety and Efficacy of Telapristone Acetate (Proellex®) Administered Vaginally for the Treatment of Uterine Fibroids". The primary objective of this study is to determine the safety and efficacy of two vaginal doses of Proellex® administered for up to 2 courses of treatment (18 weeks each), each separated by an Off-Drug Interval (ODI), to premenopausal women with symptomatic uterine fibroids.
What is the current status of trial NCT02323646?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 42 participants. The study started on 2015-02-12. Estimated completion is 2017-04-06.
What interventions are being tested in trial NCT02323646?
The interventions under investigation include: Placebo (DRUG), Telapristone Acetate (DRUG).
Who is sponsoring clinical trial NCT02323646?
This trial is sponsored by Repros Therapeutics, which has 50 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.